500 related articles for article (PubMed ID: 31419130)
21. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
[TBL] [Abstract][Full Text] [Related]
22. Sequencing of ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer.
Gadgeel SM
Curr Treat Options Oncol; 2017 Jun; 18(6):36. PubMed ID: 28534251
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic-Based Drug-Drug Interactions with Anaplastic Lymphoma Kinase Inhibitors: A Review.
Zhao D; Chen J; Chu M; Long X; Wang J
Drug Des Devel Ther; 2020; 14():1663-1681. PubMed ID: 32431491
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological and clinical properties of lorlatinib in the treatment of
El Darsa H; Abdel-Rahman O; Sangha R
Expert Opin Pharmacother; 2020 Sep; 21(13):1547-1554. PubMed ID: 32511029
[TBL] [Abstract][Full Text] [Related]
25. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
26. Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer.
Iams WT; Lovly CM
Cancer J; 2015; 21(5):378-82. PubMed ID: 26389762
[TBL] [Abstract][Full Text] [Related]
27. Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.
Karachaliou N; Santarpia M; Gonzalez Cao M; Teixido C; Sosa AE; Berenguer J; Rodriguez Capote A; Altavilla G; Rosell R
Expert Opin Investig Drugs; 2017 Jun; 26(6):713-722. PubMed ID: 28463570
[TBL] [Abstract][Full Text] [Related]
28. Alectinib for the treatment of ALK-positive stage IV non-small cell lung cancer.
Wong KM; Noonan S; O'Bryant C; Jimeno A
Drugs Today (Barc); 2015 Mar; 51(3):161-70. PubMed ID: 25876560
[TBL] [Abstract][Full Text] [Related]
29. [Therapeutic strategies in advanced ALK positive non-small cell lung cancer].
Tiotiu A; Billon Y; Vaillant P; Menard O; Hofman P; Mascaux C
Rev Mal Respir; 2019 Dec; 36(10):1107-1116. PubMed ID: 31727555
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non‑small cell lung cancer (Review).
Wang L; Wang W
Oncol Rep; 2021 Jan; 45(1):13-28. PubMed ID: 33200229
[TBL] [Abstract][Full Text] [Related]
31. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.
Mok TSK; Crino L; Felip E; Salgia R; De Pas T; Tan DSW; Chow LQM
Cancer Treat Rev; 2017 Apr; 55():181-189. PubMed ID: 28427013
[TBL] [Abstract][Full Text] [Related]
32. Treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: update and perspectives.
Ryser CO; Diebold J; Gautschi O
Curr Opin Oncol; 2019 Jan; 31(1):8-12. PubMed ID: 30394941
[TBL] [Abstract][Full Text] [Related]
33. Upfront Management of ALK-Rearranged Metastatic Non-small Cell Lung Cancer: One Inhibitor Fits All?
Tabbò F; Passiglia F; Novello S
Curr Oncol Rep; 2021 Jan; 23(1):10. PubMed ID: 33387080
[TBL] [Abstract][Full Text] [Related]
34. Anaplastic Lymphoma Kinase Inhibitors in Non-Small Cell Lung Cancer.
Straughan DM; Azoury SC; Shukla V
Curr Drug Targets; 2016; 17(6):739-45. PubMed ID: 26073862
[TBL] [Abstract][Full Text] [Related]
35. Anaplastic Lymphoma Kinase Mutation-Positive Non-Small Cell Lung Cancer.
Serritella AV; Bestvina CM
Thorac Surg Clin; 2020 May; 30(2):137-146. PubMed ID: 32327172
[TBL] [Abstract][Full Text] [Related]
36. Background and rationale of the eXalt3 trial investigating X-396 in the treatment of ALK+ non-small-cell lung cancer.
Singhi EK; Horn L
Future Oncol; 2018 Aug; 14(18):1781-1787. PubMed ID: 29506392
[TBL] [Abstract][Full Text] [Related]
37. Anaplastic lymphoma kinase tyrosine kinase inhibitor-induced hepatic failure in lung cancer patients: A study of signal mining and analysis of the FDA adverse event reporting system database.
Zhou Z; Wang C; Ying L; Jin M; Zhang F; Shi D
J Clin Pharm Ther; 2021 Aug; 46(4):1148-1154. PubMed ID: 33768534
[TBL] [Abstract][Full Text] [Related]
38. Management of CNS disease in ALK-positive non-small cell lung cancer: Is whole brain radiotherapy still needed?
Wrona A
Cancer Radiother; 2019 Sep; 23(5):432-438. PubMed ID: 31331844
[TBL] [Abstract][Full Text] [Related]
39. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
Gadgeel SM
Future Oncol; 2018 Aug; 14(18):1875-1882. PubMed ID: 29536761
[TBL] [Abstract][Full Text] [Related]
40. Brigatinib versus crizotinib for ALK-positive NSCLC.
Stirrups R
Lancet Oncol; 2018 Nov; 19(11):e585. PubMed ID: 30293790
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
